◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › PMCB

PharmaCyte Biotech, Inc. (PMCB) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

PharmaCyte Biotech, Inc. (PMCB) operates in the Biotechnology industry and is headquartered in Las Vegas, United States with about 2 employees. Its market capitalization is roughly $8 million. In the fiscal year ended 2025-04-30, PMCB reported $0M in revenue and $31M in net income.

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States.

Interactive charts & full statements →

PMCB Revenue & Earnings History — Annual Income Statement

Income statement2025-04-302024-04-302023-04-302022-04-30
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($4M)($6M)($6M)($4M)
Net Income$31M$0M($4M)($4M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PMCB Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-01-312025-10-312025-07-312025-04-302025-01-312024-10-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($2M)($1M)($1M)($1M)($1M)
Net Income$1M($7M)($8M)$12M($3M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PMCB Free Cash Flow History

PMCB Balance Sheet History

Balance sheet2025-04-302024-04-302023-04-302022-04-30
Total Assets$55M$60M$73M$91M
Total Liabilities$3M$20M$1M$1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PMCB viewer.

Other Companies in Biotechnology

← PMAXAll stocksPMEC →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.